It's famous that genetic variability in AMP metabolism could be clinically pertinent due to highly polymorphic nature of CYP2D6. In theory, CYP2D6 bad metabolizers may be envisioned to need smaller doses of AMP and/or be much more vulnerable to adverse effects from regimen medical doses, when CYP2D6 ultra-speedy metabolizers may be anticipated to a